189 related articles for article (PubMed ID: 38594611)
1. Proteomics study of primary and recurrent adamantinomatous craniopharyngiomas.
Deng H; Lei T; Liu S; Hao W; Hu M; Xiang X; Ye L; Chen D; Li Y; Liu F
Clin Proteomics; 2024 Apr; 21(1):29. PubMed ID: 38594611
[TBL] [Abstract][Full Text] [Related]
2. TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.
Liu Y; Wang CH; Li DL; Zhang SC; Peng YP; Peng JX; Song Y; Qi ST; Pan J
Oncotarget; 2016 Aug; 7(31):50564-50574. PubMed ID: 27409178
[TBL] [Abstract][Full Text] [Related]
3. Immune Microenvironment of Primary and Recurrent Craniopharyngiomas: A Study of the Differences and Clinical Significance.
Lin D; Wang Y; Zhou Z; Lin Z
World Neurosurg; 2019 Jul; 127():e212-e220. PubMed ID: 30880197
[TBL] [Abstract][Full Text] [Related]
4. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
[TBL] [Abstract][Full Text] [Related]
5. Integrative analyses identify HIF-1α as a potential protective role with immune cell infiltration in adamantinomatous craniopharyngioma.
Gao Q; Luo J; Pan J; Zhang L; Song D; Zhang M; Xu D; Guo F
Front Immunol; 2022; 13():949509. PubMed ID: 36091021
[TBL] [Abstract][Full Text] [Related]
6. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
[No Abstract] [Full Text] [Related]
7. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
[TBL] [Abstract][Full Text] [Related]
8. Expression of enamel proteins and LEF1 in adamantinomatous craniopharyngioma: evidence for its odontogenic epithelial differentiation.
Sekine S; Takata T; Shibata T; Mori M; Morishita Y; Noguchi M; Uchida T; Kanai Y; Hirohashi S
Histopathology; 2004 Dec; 45(6):573-9. PubMed ID: 15569047
[TBL] [Abstract][Full Text] [Related]
9. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
[TBL] [Abstract][Full Text] [Related]
10. High expression levels of CXCL12 and CXCR4 predict recurrence of adamanti-nomatous craniopharyngiomas in children.
Gong J; Zhang H; Xing S; Li C; Ma Z; Jia G; Hu W
Cancer Biomark; 2014; 14(4):241-51. PubMed ID: 24934367
[TBL] [Abstract][Full Text] [Related]
11. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
Esheba GE; Hassan AA
J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
[TBL] [Abstract][Full Text] [Related]
12. In-depth proteomic profiling captures subtype-specific features of craniopharyngiomas.
Kim JH; Kim H; Dan K; Kim SI; Park SH; Han D; Kim YH
Sci Rep; 2021 Oct; 11(1):21206. PubMed ID: 34707096
[TBL] [Abstract][Full Text] [Related]
13. EpCAM (CD326) is differentially expressed in craniopharyngioma subtypes and Rathke's cleft cysts.
Thimsen V; Hölsken A; Buchfelder M; Flitsch J; Fahlbusch R; Stefanits H; Losa M; Jones DT; Buslei R
Sci Rep; 2016 Jul; 6():29731. PubMed ID: 27431859
[TBL] [Abstract][Full Text] [Related]
14. CD47 promotes the proliferation and migration of adamantinomatous craniopharyngioma cells by activating the MAPK/ERK pathway, and CD47 blockade facilitates microglia-mediated phagocytosis.
Zhang H; Wang C; Fan J; Zhu Q; Feng Y; Pan J; Peng J; Shi J; Qi S; Liu Y
Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12795. PubMed ID: 35156226
[TBL] [Abstract][Full Text] [Related]
15. Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
Moreno-Torres B; Campos-Martín Y; Meléndez B; Garcia Martin RM; Vicente A; Rodríguez de Lope Á; Alen JF; Mollejo M; Hernández-Laín A
Clin Neuropathol; 2021; 40(1):26-35. PubMed ID: 33040839
[TBL] [Abstract][Full Text] [Related]
16. The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment.
Whelan R; Prince E; Gilani A; Hankinson T
J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32075140
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
Martinez-Gutierrez JC; D'Andrea MR; Cahill DP; Santagata S; Barker FG; Brastianos PK
Neurosurg Focus; 2016 Dec; 41(6):E2. PubMed ID: 27903124
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics analysis and validation of the critical genes associated with adamantinomatous craniopharyngioma.
Fang C; Zhou L; Huang H; Xu HT; Hong T; Zheng SY
Front Oncol; 2022; 12():1007236. PubMed ID: 36387067
[TBL] [Abstract][Full Text] [Related]
19. Multi-omics analysis of adamantinomatous craniopharyngiomas reveals distinct molecular subgroups with prognostic and treatment response significance.
Wang X; Zhao C; Lin J; Liu H; Zeng Q; Chen H; Wang Y; Xu D; Chen W; Xu M; Zhang E; Lin D; Lin Z
Chin Med J (Engl); 2024 Apr; 137(7):859-870. PubMed ID: 37565822
[TBL] [Abstract][Full Text] [Related]
20. Correlations between the expression of molecules in the TGF-β signaling pathway and clinical factors in adamantinomatous craniopharyngiomas.
Jin L; Cai K; Wu W; Xiao Y; Qiao N; Liu F; Ru S; Cao L; Zhu H; Bai J; Liu C; Li C; Zhao P; Zhang Y; Gui S
Front Endocrinol (Lausanne); 2023; 14():1167776. PubMed ID: 37854185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
